Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 6/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21185054 | 0.84 | CYP4F2 (0.45) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL26964613 | 0.83 | CYP4F2 (0.44) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL25918978 | 0.82 | ALDH1A1 (0.42) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL14903852 | 0.81 | CYP4F2 (0.47) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL24702054 | 0.81 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL26964763 | 0.81 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL2896462 | 0.79 | ALDH1A1 (0.48) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL31641559 | 0.79 | ALDH1A1 (0.47) | ALDH1A1POLBLMNAKDM5BRET | |
| SCHEMBL30045758 | 0.78 | ALDH1A1 (0.52) | ALDH1A1POLBLMNARETCYP4F2 | |
| SCHEMBL1475947 | 0.77 | ALDH1A1 (0.43) | ALDH1A1POLBLMNAKDM5BRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | ALDH1A1 3717/4885POLB 249/4885LMNA 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.